Table 1.

Clinically significant disease frequency based on predominant symptom/indications

Symptoms (total)	Findings	No (%)	Diagnostic yield	OR (95% CI, p value)
Diarrhoea (total=188)	CRC	5 (3)	5.3% (n=59/1116)	3.15 (2.22 to 4.47, p<0.0001)
	HRA	7 (4)
	Angiodysplasia	2 (1)
	Inflammation—IBD	31 (16)
	Inflammation—Microscopic Colitis	7 (4)
	Inflammation—non-specific	7 (4)
	Negative	129 (69)
PR bleeding (total=148)	CRC	9 (6)	2.9% (n=32/1116)	1.9 (1.24 to 2.9, p=0.003)
	HRA	12 (8)
	Inflammation—IBD	6 (4)
	Inflammation—microscopic colitis	1 (1)
	Inflammation—non-specific	3 (2)
	Angiodysplasia	1 (1)
	Negative	116(79)
Anaemia (total=212)	CRC	4 (2)	2.2% (n=25/1116)	0.83 (0.53 to 1.29, p=0.4)
	HRA	12 (6)
	Inflammation—IBD	5 (2)
	Inflammation—non-specific	2 (1)
	Angiodysplasia	2 (1)
	Negative	187 (88)
Weight loss (total=37)	HRA	3 (8)	0.4% (n=4/1116)	0.79 (0.28 to 2.24, p= 0.65)
	Inflammation—IBD	1 (3)
	Negative	35 (94)
Constipation (total=57)	HRA	2 (4)	0.4% (n=5/1116)	0.57 (0.22 to 1.45, p=0.12)
	Inflammation—IBD	1 (2)
	Angiodysplasia	1 (2)
	Negative	53 (93)
Alternating constipation and diarrhoea (total=79)	CRC	1 (1)	1% (n= 12/1116)	1.23 (0.65 to 2.33, p=0.52)
	HRA	2 (3)
	Inflammation—IBD	6 (8)
	Inflammation—microscopic colitis	1 (1)
	Inflammation—non-specific	2 (3)
	Negative	67 (85)
Abdominal pain (total=104)	CRC	1 (1)	0.8% (n=9/1116)	0.7 (0.37 to 1.33, p=0.28)
	HRA	1 (1)
	Inflammation—IBD	4 (4)
	Inflammation—non-specific	3 (3)
	Negative	95 (91)

CRC, colorectal cancer; HRA, high-risk adenoma; IBD, inflammatory bowel disease; PR, per rectum.